195 related articles for article (PubMed ID: 24590477)
1. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia.
Gomes MZ; Jiang Y; Mulanovich VE; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 May; 58(5):2775-80. PubMed ID: 24590477
[TBL] [Abstract][Full Text] [Related]
2. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
[TBL] [Abstract][Full Text] [Related]
5. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
8. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
10. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
11. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
12. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
13. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
14. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
16. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
17. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
[TBL] [Abstract][Full Text] [Related]
18. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
